Cytopacx presents a portfolio of regenerative medicine technologies centered on exosome-based therapies and probiotic formulations. The company develops neural stem cell‑derived exosomes to encourage nerve regeneration and mesenchymal stem cell‑derived exosomes for tissue repair. It also produces proprietary probiotic blends (“MeiSanèŒâ€) crafted to support digestive and skin health. It operates with integrated GMP‑grade production, GLP‑compliant research labs, and pilot‑scale manufacturing capabilities. Its services include R&D collaborations, strain selection, exosome extraction, and formulation development for both therapeutic and wellness applications. The company positions itself as a biotech innovator in regenerative and precise medicine.
